Previous 10 | Next 10 |
Evotec SE (NASDAQ:EVO) announced on Monday that it received a €3 million worth of milestone payment from German conglomerate Bayer AG (OTCPK:BAYZF) (OTCPK:BAYRY) for clinical work related to a potential treatment for diabetic neuropathic pain ("DNP"). The payment was triggered by the d...
FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR DIABETIC NEUROPATHIC PAIN HAMBURG, GERMANY / ACCESSWIRE / March 21, 2022 / Evo...
LAUNCH OF E.MPD, THE LEADING GLOBAL MOLECULAR PATIENT DATABASE ROLL-OUT AND ACCELERATION OF AI/ML PRECISION TECHNOLOGIES TO INCREASE PROBABILITY OF SUCCESS ("POS") IN RESEARCH, DEVELOPMENT, AND MANUFACTURING EXPANSION OF MANAGEMENT BOARD WITH NEW CHIEF BUSINESS OFFICER (CBO) DR MA...
EVOTEC RECEIVES ACCESS TO AN INTERNATIONAL COHORT OF NEPHROTIC SYNDROME PATIENTS COORDINATED BY THE UNIVERSITY OF BRISTOL THE COHORT PROVIDES LONGITUDINAL ACCESS NOT ONLY TO CLINICAL DATA BUT IN PARTICULAR ALSO TO BIOSPECIMENS EVOTEC WILL LEVERAGE ITS MULTI-OMICS ANALYSIS PLATFORM...
Gainers: TDCX (NYSE:TDCX) +16%. ALJ Regional Holdings (NASDAQ:ALJJ) +8%. Nxt-ID (NASDAQ:NXTD) +8%. Microvast Holdings (NASDAQ:MVST) +7%. Archer Aviation (NYSE:ACHR) +7%. Losers: SkyWest (NASDAQ:SKYW) -21%. GrafTech International (NYSE:EAF) -9%. Alpine 4 Holdings (NASDAQ:AL...
Gainers: Snap (NYSE:SNAP) +52%. Bill.com Holdings (NYSE:BILL) +31%. Indonesia Energy Corporation (NYSE:INDO) +28%. eGain (NASDAQ:EGAN) +22%. Sphere (NASDAQ:ANY) +21%. Standard Lithium (NYSE:SLI) +17%. Aurora Innovation (NASDAQ:AUR) +17%. Unity Software (NYSE:U) +17%. Astria Therapeutics (NASD...
Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...
HAMBURG, GERMANY / ACCESSWIRE / February 4, 2022 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor ant...
PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS HAMBURG, GERMANY / ACCESSWIRE / January 25, 2022 / Evotec SE (Frankfurt Stock Exchange: E...
Vancouver, Kelowna, Delta, BC - January 21, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Tech, Automotive, Real Estate, Biotech, Food & Beverage, Cannabis, eSport and Mini...
News, Short Squeeze, Breakout and More Instantly...
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a mul...
Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security HAMBURG, GERMANY...
Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimiz...